Executive Summary
Today's 50 filings reveal a market defined by aggressive liability management, SPAC and merger activity, and divergent operating performance. Embraer delivered record Q3 revenue (+17% YoY) and raised 2026 guidance, while Brookfield Business Partners saw revenue fall 32.4% YoY due to dispositions.
Distressed refinancings at Xerox (10.25% secured notes) and Pyxus (exchange offer stripping covenants) highlight rising credit stress, while Mirum's positive Phase 3 HDV data offers a bright spot in biotech. Insider and institutional flows show continued preference for mega-cap tech and ETFs, with Stephens favoring small/mid-cap healthcare. SPAC activity is robust, with BHAV's $400M Nemi deal and Quantum Space's corrected launch timeline. Overall, the filings underscore a market rewarding operational execution and strategic M&A while penalizing balance-sheet weakness.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Schedule 13G · 13F · S-3 · DEFA14A · 8-K · Schedule 13D · 20-F · 425 · 10-Q
Tracking the trend? Catch up on the prior US SEC Filings Daily Market Digest digest from November 09, 2026.
Investment Signals (10)
- Embraer (ERJ) (BULLISH)▲
Q3 revenue up 17% YoY to $2.35B, record backlog $35.7B (+14% YoY), adjusted EBIT margin expanded to 10.9% from 8.6%, and management raised 2026 revenue guidance to $8.4-8.6B and FCF to >$700M
- Mirum Pharmaceuticals (MIRM) (BULLISH)▲
Phase 3 AZURE-4 trial met primary endpoint with 59% response (300mg) vs 0% control (p≤0.0001), BLA submission planned H1 2027, potential launch Q4 2027
- Stride (LRN) (BULLISH)▲
Activist Fivespan acquired 5.3% stake for ~$178.7M, secured board seat and formed Capital Allocation Committee, standstill caps ownership at 7.5%
- HIVE Digital (HIVE) (BULLISH)▲
HPC revenue surged 70.7% YoY to $8.8M, gross margin improved to 35.6%, adjusted EBITDA up 85% QoQ to $24.8M, ~$185M contracted ARR
- Regency Centers (REG) (BULLISH)▲
Entered new $1.5B revolver and $550M term loan, extending maturities to 2030/2031 with accordion up to $3.0B, improving liquidity
- Brookfield Business Partners (BBU) (BULLISH)▲
Net income attributable to unitholders swung to $43M profit from $109M loss, despite revenue decline from dispositions; completed $1.3B Antylia and $2.6B First National acquisitions
- Accelevation Holdings (private)▲
Olympus Growth Fund VIII holds 85.4% post-IPO, indicating strong sponsor commitment [NEUTRAL/BULLISH]
- Synchrony Financial (SYF) ↓ (NEUTRAL)▲
Continues monthly charge-off and delinquency disclosures, providing transparency; no red flags in filing body
- Atour Lifestyle (ATAT) (BULLISH)▲
Filed 6-K with Q3 results and dividend announcement, details in exhibits; potential positive catalyst
- On Holding (ONON) (NEUTRAL)▲
Filed 6-K with Q3 results, details in exhibits; watch for growth trajectory
Risk Flags (10)
- Xerox (XRX) [HIGH RISK]▼
Exchanging 5.5% 2028 notes for 10.25% secured 2030 notes, significantly increasing interest expense and signaling credit deterioration
- Pyxus International (PYX) [HIGH RISK]▼
Exchange offer strips most covenants, eliminates change-of-control repurchase obligation, subordinates existing notes, and releases all collateral—a broad erosion of noteholder protections
- Ashford Hospitality Trust (AHT) [HIGH RISK]▼
AFFO per share negative at $(2.22), preferred dividends suspended, 93% floating-rate debt at 8.4% average rate, exposing to rate volatility
- Turkcell (TKC) (BEARISH)▼
9M26 operating profit fell 9.3% YoY, gross margin compressed as cost of revenue rose 8.7% vs revenue +5.8%, finance costs jumped 59.8%
- Focus Universal (FCUV) (BEARISH)▼
Net loss widened to $(1.39M) from $(1.17M) YoY despite revenue jump, as operating expenses rose 62%
- Abony Acquisition Corp. I (AACIU)↓ (BEARISH)▼
Shareholders' deficit ballooned to $7.1M from $74.7K due to $16.5M accretion of Class A shares to redemption value
- Quantum Space (SPAC) (BEARISH)▼
Launch timeline slipped from Q2 2027 to H2 2027, NASA payloads cut from three to two, no financial guidance provided
- Werewolf Therapeutics (HOWL) (BEARISH)▼
Merger values Werewolf at only $47.5M, existing holders to own just 6.4% of combined company, lead asset neridronate not FDA approved
- Chemomab Therapeutics (CMMB) (BEARISH)▼
Merger with Scipher assigns Chemomab $48M valuation, existing Scipher securities cancelled for no consideration, deal contingent on dilutive PIPE
-
Acquired properties from affiliate TIAA at $20.6M, with rental revenue declining ~0.7% annualized vs FY2025 run-rate, short lease duration [NEUTRAL/BEARISH]
Opportunities (10)
- Embraer (ERJ) (OPPORTUNITY)◆
Record backlog and raised guidance present upside; stock may re-rate as deliveries accelerate in H2 2026
- Mirum Pharmaceuticals (MIRM) (OPPORTUNITY)◆
Positive Phase 3 data for brelovitug in HDV with BLA submission H1 2027; potential best-in-class therapy for chronic HDV
- Stride (LRN) (OPPORTUNITY)◆
Activist involvement could unlock value through capital allocation review and board refresh; Fivespan's $178.7M stake signals conviction
- HIVE Digital (HIVE) (OPPORTUNITY)◆
HPC segment growth and $185M contracted ARR provide revenue visibility; adjusted EBITDA inflection could drive re-rating
- BHAV Acquisition Corp (SPAC)↓ (OPPORTUNITY)◆
$400M merger with Nemi Corp (EV maker) at $10/share; super-voting shares for founders may align incentives
- Atour Lifestyle (ATAT) (OPPORTUNITY)◆
Q3 results and dividend announcement could surprise positively; Chinese travel recovery play
- On Holding (ONON) (OPPORTUNITY)◆
Q3 results may show continued strong growth in running shoes; watch for guidance
- Synchrony Financial (SYF)↓ (OPPORTUNITY)◆
Monthly credit data could show improving charge-offs, potentially signaling consumer health
- Accelevation Holdings (private) (OPPORTUNITY)◆
Post-IPO sponsor control may lead to strategic initiatives; watch for lock-up expiry
- Regency Centers (REG) (OPPORTUNITY)◆
Improved credit facility provides flexibility for acquisitions; strong balance sheet
Sector Themes (6)
- Liability Management Wave◆
Xerox and Pyxus are extending maturities and stripping covenants, indicating rising refinancing stress among leveraged companies. Expect more exchange offers as rates stay elevated.
- SPAC Resurgence◆
BHAV's $400M Nemi deal, Quantum Space's going-public transaction, and multiple Goldman 13G filings in blank-check companies suggest renewed SPAC activity, particularly in EV and space sectors.
- Divergent Industrial Performance◆
Embraer (record revenue, raised guidance) contrasts with Brookfield Business Partners (revenue -32.4% YoY from dispositions) and Turkcell (margin compression), highlighting uneven global industrial recovery.
- Healthcare Innovation◆
Mirum's positive Phase 3 data and Stephens' 13F overweight in small/mid-cap healthcare (Repligen, Illumina, Halozyme) indicate selective appetite for biotech innovation despite sector volatility.
- ETF Dominance in Institutional Portfolios◆
Hudson, Vawter, and Bank Hapoalim 13Fs show heavy ETF allocations, reflecting passive investing trends and a preference for diversified exposure amid uncertainty.
- Insider and Activist Activity◆
Fivespan's activist stake in Stride and Goldman's numerous 13G filings (mostly passive) show engaged investors seeking value in education and small-cap names.
Watch List (8)
- Xerox (XRX)👁
Exchange offer expires Nov 13, 2026; watch for participation rate and potential default risk if exchange fails.
- Pyxus International (PYX)👁
Early tender deadline Nov 24, 2026; consent solicitation could weaken noteholder protections, monitor for bondholder pushback.
- Mirum Pharmaceuticals (MIRM)👁
BLA submission H1 2027; watch for FDA interactions and competitive landscape in HDV.
- Embraer (ERJ)👁
Q4 deliveries and 2027 guidance; watch for execution on raised 2026 targets.
- Quantum Space (SPAC)👁
Launch timeline H2 2027; watch for further delays and financial details.
-
Shareholder vote on Nemi merger; watch for redemption levels and regulatory approvals.
- Stride (LRN)👁
Capital Allocation Committee outcomes; watch for strategic initiatives and 2026 annual meeting.
-
Monthly charge-off data; watch for consumer credit deterioration.
Filing Analyses
(50)
10-11-2026
Intracoastal Capital LLC, together with Mitchell P. Kopin and Daniel B. Asher, filed an amended Schedule 13G reporting deemed beneficial ownership of 966,953 shares of Innovative Eyewear common stock, equal to approximately 9.99% of the company. The shares are issuable only upon exercise of Intracoastal Warrant 1, which carries a 9.99% blocker provision; without the blocker provisions across three warrants, the group could be deemed to beneficially own 6,667,829 shares. The filing is a passive-investor disclosure under Rule 13d-1(c) and states the securities were not acquired to influence control of the issuer.
- · Reporting Persons are Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (Delaware LLC)
- · Ownership is entirely warrant-derived; no direct share purchases disclosed
- · Warrant 1 blocker caps exercise at 9.99%; Warrants 2 and 3 capped at 4.99%
- · Filing made under Rule 13d-1(c) as a passive investor; no control intent certified
- · Issuer is Innovative Eyewear Inc (CIK 0001808377), Ophthalmic Goods (SIC 3851), incorporated in Florida
- · CUSIP 45791D208; event date September 30, 2026; filed November 10, 2026
- · Mr. Kopin and Intracoastal office: 245 Palm Trail, Delray Beach, FL 33483; Mr. Asher office: 1011 Lake Street, Suite 311, Oak Park, IL 60301
10-11-2026
Stephens Investment Management Group LLC filed its Q3 2026 13F-HR disclosing 172 total holdings valued at approximately $9.29B as of September 30, 2026. The portfolio is heavily concentrated in healthcare and technology names, with top positions including Repligen ($183.5M), Henry Schein-adjacent healthcare holdings, FirstCash ($164.6M), Illumina ($160.9M), Halozyme ($156.0M), Exelixis ($151.6M) and Twist Bioscience ($150.8M). However, several mega-cap positions were minimal or trimmed to zero-change stubs — Alphabet ($605.6K), Amazon ($581.0K), Microsoft ($938.1K), Meta ($548.2K) and NVIDIA ($1.0M) — indicating the manager favors small/mid-cap growth over mega-cap tech.
- · Filing is a 13F-HR for the period ending 09-30-2026, filed 11-10-2026 under SEC File Number 028-11261
- · Filer address: 9 Greenway Plaza, Suite 1900, Houston, TX 77046; mailing address 111 Center Street, Little Rock, AR 72201
- · Former company name was Stephens Inc. (name changed 2005-01-14)
- · Mega-cap tech positions are tiny relative to portfolio: NVIDIA $1,009,440 (4,420 sh), Microsoft $938,094 (1,829 sh), Alphabet $605,581 (1,760 sh), Amazon $581,018 (2,332 sh), Meta $548,236 (756 sh)
- · Other large positions: DigitalOcean $98.1M, HEICO $99.6M, Burlington Stores $96.9M, Guidewire $88.8M, Leonardo DRS $88.3M, Kratos Defense $86.8M, HealthEquity $86.4M, BWX Technologies $85.8M
- · Several positions show zero share change (e.g., Tractor Supply 130,157 sh, Alphabet, Amazon, Microsoft, NVIDIA, Meta, Palantir, TSMC, ASML)
- · Portfolio spans US and international names including Israel-based (Camtek, JFrog, Kornit, TAT Technologies), UK (TechnipFMC), Switzerland (Sportradar), Netherlands (ASML), Taiwan (TSMC)
10-11-2026
Xerox filed an S-3/A registering the resale of common stock issued to holders of its 5.500% Senior Notes due 2028 who agreed to exchange those notes for newly issued 10.250% Senior Secured First Lien Notes due 2030, accrued interest cash, and common stock (the 'Exchange Issuance'). The exchange support agreement was signed October 29, 2026, with exchange agreements expected November 13, 2026; Xerox will receive no proceeds from resales. The filing reflects a debt-maturity extension and higher-coupon secured refinancing, with the largest selling stockholder being Millennium-affiliated entities holding 3,518,225 shares (2.56%), which would fall to 2,591,263 shares (1.89%) after selling 926,962 shares.
- · Exchange support agreement dated October 29, 2026; exchange agreements expected to be executed November 13, 2026
- · Exchanging holders receive cash for accrued and unpaid interest on the 2028 Notes plus common stock, or additional new notes if unable to hold equity
- · Registration statement number 333-299708
- · Xerox Holdings Corporation is a New York corporation organized in 2019, headquartered at 401 Merritt 7, Norwalk, Connecticut
- · Selling stockholders include 27 named funds/entities; most hold less than 1% each
- · Millennium affiliates held warrants to purchase 210,338 and 1,928,534 shares plus direct holdings of 156,922 and 295,469 shares as of October 23, 2026
10-11-2026
Chemomab Therapeutics filed a DEFA14A supplement updating its proxy statement/prospectus for its merger with Scipher Medicine, under which Chemomab Israel will domesticate into a Delaware parent and merge with Scipher, with the combined company (Scipher Medicine Corporation, ticker SCIP) expected to close in Q1 2027 and list on Nasdaq. The deal assigns Chemomab a $48M valuation and Scipher $102M (aggregate $150M), with former Scipher noteholders owning ~68% and Chemomab holders ~32% pre-PIPE. However, Scipher common/preferred stock, options, warrants and 2025 Notes are cancelled for no consideration, the merger is conditioned on a dilutive Concurrent PIPE Investment, and the End Date of March 31, 2027 (extendable 60 days) leaves completion uncertain.
- · Domestication Exchange Ratio expected ~0.0021 (0.168 on an ADS basis), so each ADS converts into 0.168 shares of Chemomab Parent Common Stock
- · Combined company headquarters will be in Durham, North Carolina, trading as 'Scipher Medicine Corporation' under symbol 'SCIP'
- · Merger End Date is March 31, 2027, automatically extendable by 60 days for regulatory/registration conditions
- · Record date for the shareholder meeting is October 29, 2026; ADSs issued after that date (including November 2026 ADSs) cannot vote
- · CVRs are non-transferable except in limited circumstances, carry no voting/dividend rights, are unregistered, and accrue no interest
- · Non-Participating Notes will be subordinated and cancelled for no consideration rather than converted
- · Combined company plans to advance nebokitug into a Phase 2 rheumatoid arthritis trial using PrismRA patient stratification
10-11-2026
Hudson Portfolio Management LLC filed its Q3 2026 13F-HR disclosing 120 holdings valued at $131,195,678 as of September 30, 2026. The portfolio is heavily weighted toward ETFs (iShares, SPDR, Invesco, PIMCO) alongside large-cap equities, with the largest positions being Taiwan Semiconductor ($7.67M), Alphabet Class C ($7.55M), McKesson ($4.59M), iShares MSCI Japan ETF ($4.52M), and iShares 0-5 Yr TIPS ETF ($3.54M). The filing is a routine quarterly holdings disclosure with no period-over-period comparison data provided, so no growth or decline metrics can be calculated.
- · Filing is a 13F-HR Holdings Report for the period ending 09-30-2026, filed 11-10-2026 under SEC File Number 028-21203
- · All 120 positions are held solely (SOLE voting authority) with no shared or no-vote allocations reported
- · Portfolio includes numerous country/regional ETFs (Japan, Italy, Eurozone, Latin America, Mexico, Taiwan, New Germany Fund) indicating a diversified international allocation
- · Significant fixed-income ETF exposure via iShares 1-5YR, 0-5 Yr TIPS, 3-7 Yr Treasury, 5-10 Yr Investment Grade, and Floating Rate Note ETFs
- · Notable international ADR holdings include Infosys (136,205 shares), Honda Motor (47,440 shares), Petrobras (39,700 shares), and Vodafone (28,557 shares)
- · No period-over-period holdings comparison is included in this filing, so quarter-over-quarter position changes cannot be determined
10-11-2026
Regency Centers, L.P. entered into a Seventh Amended and Restated Credit Agreement on November 10, 2026, providing a $1.5 billion senior unsecured revolving credit facility maturing November 8, 2030, and a $550.0 million senior unsecured delayed draw term loan facility maturing February 10, 2031. The agreement includes an uncommitted accordion allowing total commitments up to $3.0 billion, a $50.0 million letter of credit sublimit, and a $125.0 million swingline subfacility. Pricing is credit-rating based, with SOFR margins of 0.625%–1.350% on the revolver and 0.675%–1.550% on the term loan, plus facility fees of 0.100%–0.300% and a 0.125% ticking fee on unfunded term commitments after 91 days.
- · Revolving Credit Facility matures November 8, 2030; Term Loan Facility matures February 10, 2031
- · Term loan availability period runs from Closing Date to no later than May 10, 2027, drawable in up to six borrowings
- · Base rate margins range 0.000%–0.350% for the revolver and 0.000%–0.550% for the term loan
- · No amortization payments required on term loans prior to maturity; repaid term loans may not be reborrowed
- · Financial covenants include indebtedness to total asset value, unsecured indebtedness to unencumbered asset value, adjusted EBITDA to fixed charges, and secured indebtedness to total asset value
- · Maximum leverage ratios may be increased for the fiscal quarter of a material acquisition and the four subsequent quarters
- · Distributions restricted during certain events of default, with exception for distributions required to maintain REIT status
- · Prepayment permitted at any time without premium or penalty, subject to customary SOFR breakage costs
- · Agreement amends and restates the Sixth Amended and Restated Credit Agreement dated January 18, 2024 (as amended July 8, 2024)
10-11-2026
Regional Management Corp. filed an 8-K on November 10, 2026, disclosing under Item 7.01 (Regulation FD) an investor presentation (Exhibit 99.1) to be used by management in meetings with bankers, investors, and others commencing that day, also posted on the company's website. The filing contains no financial results, transaction terms, or performance metrics — only the disclosure of the presentation and related exhibits. The filing was signed by Harpreet Rana, EVP and Chief Financial and Administrative Officer.
- · Exhibit 99.1 is the investor presentation dated November 10, 2026; Exhibit 104 is the Cover Page Interactive Data File (Inline XBRL)
- · Presentation is available on the company's website at www.regionalmanagement.com
- · Information under Item 7.01 is not deemed 'filed' under Section 18 of the Exchange Act and is not incorporated by reference except by specific reference
- · Company incorporated in Delaware; IRS Employer Identification No. 57-0847115; Commission File Number 001-35477
- · Principal executive offices located at 979 Batesville Road, Suite B, Greer, South Carolina 29651; telephone (864) 448-7000
- · Company is not an emerging growth company (box unchecked)
10-11-2026
OGP VIII, LLC and affiliated reporting persons jointly filed a Schedule 13G disclosing beneficial ownership of 192,191,501 shares of Accelevation Holdings Class A common stock, representing 85.4% of the class, following the company's October 1, 2026 IPO. The stake includes 104,977,528 shares issuable upon conversion of Series B Units (held via Accelevation Investment Holdings LLC at 46.7%) plus 87,213,973 directly held shares (via Accelevation Pubco Holdings LP at 38.8%). The concentration reflects pre-IPO sponsor control by Olympus Growth Fund VIII entities, with Robert S. Morris as Managing Member of the general partner.
- · Filing made under Rule 13d-1(d); reporting persons disclaim beneficial ownership under Rule 13d-4
- · Olympus Funds have right to appoint/remove members of boards of managers of Accelevation Pubco Holdings and Investment Holdings
- · Reported amounts reflect dispositions and conversions in connection with IPO closing on October 1, 2026
- · Issuer incorporated in Delaware, SIC code 3620 (Electrical Industrial Apparatus), fiscal year end 12/31
- · Joint filing agreement dated November 10, 2026
10-11-2026
Intracoastal Capital LLC, together with Mitchell P. Kopin and Daniel B. Asher, filed an amended Schedule 13G reporting beneficial ownership of 176,165 shares of Silo Pharma common stock, equal to approximately 9.99% of the outstanding shares as of September 30, 2026. The reported position consists of only 994 directly held shares plus 175,171 shares underlying four warrants, with the 9.99% figure driven by warrant blocker provisions; absent those blockers, beneficial ownership would have been 637,299 shares. The filing is a passive-holder disclosure certifying the securities were not acquired to influence control of the issuer.
- · Only 994 of the 176,165 reported shares are directly held; the remaining 175,171 are warrant-underlying shares
- · Warrant blocker provisions cap reported ownership at 9.99%, masking a potential 637,299-share (much larger) economic exposure
- · Warrants 6 and 7 carry tighter 4.99% blockers versus 9.99% on Warrants 1-5
- · Filing made under Rule 13d-1(c) as a passive investor; certifies no intent to influence control
- · Issuer formerly named Uppercut Brands, Inc. (changed 2019), Point Capital, Inc. (2013), and Gold Swap Inc (2011)
- · Silo Pharma incorporated in Nevada; principal address 677 N. Washington Blvd, Sarasota, FL 34236
10-11-2026
Fivespan Partners, LP (with Fivespan Partners GP, LLC and Dylan G. Haggart) filed a Schedule 13D disclosing beneficial ownership of 2,236,033 shares of Stride, Inc., or 5.3% of the 42,048,853 shares outstanding as of October 19, 2026, acquired for approximately $178.7 million. The activist stake came alongside an October 8, 2026 Cooperation Agreement under which Haggart joined the Board on October 22, 2026 and Dr. Steven Guttentag became a non-voting observer, with the Investor Group withdrawing its 2026 director nominations, shareholder proposal and Section 220 books-and-records demand. The standstill caps further ownership at 7.5% beneficial ownership and 12.5% aggregate economic exposure, while the company formed a Capital Allocation Committee co-chaired by Haggart and Brian Shepherd.
- · Reporting Persons acquired the stake based on belief the securities were undervalued and represented an attractive investment opportunity.
- · Haggart to be nominated for election at the 2026 annual meeting for a term expiring at the 2027 annual meeting; Guttentag to join the Board and its Academic and Nominating & Corporate Governance Committees immediately following the 2026 annual meeting.
- · Standstill obligations remain until the earliest of 30 days before the 2027 nomination notice deadline, specified failures concerning Board appointments, or mutual termination.
- · Fivespan granted replacement rights during the Standstill Period should either Haggart's or Guttentag's Board seat become vacant.
- · Issuer agreed to reimburse the Investor Group for certain expenses subject to a cap.
- · Haggart also serves on the Compensation Committee.
- · Source of funds was working capital of Fivespan Fund; positions may be held in margin accounts and pledged as collateral.
- · Filing signed November 10, 2026; exhibits include Joint Filing Agreement (99.1), Trading Data (99.2) and Cooperation Agreement (99.3).
10-11-2026
Meeder Asset Management Inc filed its Q3 2026 13F-HR disclosing 2,209 holdings with a total reported value of $2,004,329,796 as of September 30, 2026. The portfolio is heavily concentrated in mega-cap technology names, led by Apple (~$72.2M across multiple share classes/lots) and Alphabet Class C (~$48.2M), with sizable positions in AbbVie, AMD, Amgen, Applied Materials, Amazon, Ameriprise and Analog Devices. The filing is a routine quarterly holdings disclosure with no period-over-period comparison data included, so no growth or decline metrics can be derived from this document alone.
- · Filing is for the period ended September 30, 2026, filed November 10, 2026 (signed November 9, 2026).
- · Filer CIK 0000809443; SEC file number 028-01512; state of incorporation Ohio; fiscal year end 12/31.
- · All reported positions are held SOLE with no shared or discretionary-other voting disclosed.
- · Portfolio includes numerous small positions of 1 share (e.g., AES Corp $15, Alliant Energy $63, Ameren $99, American Electric Power $119).
- · Positions are reported in multiple separate lots for the same security (e.g., eight separate AbbVie lines, eight Apple lines, eight Alphabet Class C lines).
- · No period-over-period holdings comparison data is included in this filing, so quarter-over-quarter position changes cannot be determined from this document.
10-11-2026
Ashford Hospitality Trust reported Q3 2026 net income attributable to common stockholders of $2.5 million ($0.12/diluted share), a swing from a $(69.0) million loss ($(11.35)/share) a year earlier, as Comparable RevPAR rose 7.3% to $140.8 and Comparable Hotel EBITDA grew 6.9% to $55.5 million. However, AFFO per diluted share remained negative at $(2.22) for the quarter (improved from $(2.85)), and preferred dividends remain suspended with no near-term resumption due to elevated interest rates. Total debt fell 26.4% to $1.9 billion from $2.6 billion at year-end 2025, aided by 19 hotel sales totaling ~$796 million year to date, while interest expense declined 15.9% to $47.4 million.
- · AFFO per diluted share was $(2.22) for Q3 2026, still negative despite improving from $(2.85) a year earlier.
- · Preferred dividends remain suspended; the Board will evaluate quarterly and dividends continue to accumulate while suspended.
- · Total loans of $1.9 billion carry a blended average interest rate of 8.4%, with ~93% floating-rate and only ~7% fixed-rate, leaving the company highly exposed to rate moves.
- · Four Q3 hotel sales totaled $145.8 million ($134,300 per key) and avoided an estimated $26.7 million of CapEx, for total value of $172.5 million ($158,900 per key).
- · The new $525.0 million Highland loan is interest-only with a two-year initial term at SOFR + 5.24% (vs SOFR + 5.47% prior) and three one-year extension options.
- · Ashford Inc. has not yet purchased any shares under the 2.5% quarterly share purchase agreement; Q3 2026 purchases must be completed by March 31, 2027.
- · Total assets fell to $2,113,889 thousand from $2,833,632 thousand at December 31, 2025, and total stockholders' deficit was $(565,584) thousand.
- · Accumulated deficit stood at $(2,967,818) thousand at September 30, 2026.
10-11-2026
Oculus Inc. held its Annual Meeting of Stockholders on November 10, 2026, with 56,301,165 shares (61.58% of 91,422,569 outstanding) represented, constituting a quorum. All six director nominees were elected with roughly 99% support, auditors Davidson & Company LLP were ratified (99.79% for), and the Omnibus Equity Incentive Plan was continued (95.72% for). However, the reverse stock split authorization drew the most opposition, passing with 85.44% for versus 7.06% against and 7.50% abstaining, while say-on-pay passed at 94.56% for with 5.00% abstaining and annual say-on-pay frequency was favored by 93.20%.
- · Board reappointed Roland Perkins as President and CEO and Anton J. Drescher as Corporate Secretary and CFO immediately following the meeting.
- · Reverse stock split ratio to be set between 1-for-2 and 1-for-10 at the board's discretion, with implementation and timing also at board discretion.
- · Say-on-pay frequency approved as annual, with 93.20% support for 1 year versus 6.44% for 3 years.
- · 6,238,114 broker non-votes were ineligible to vote on director elections and most other proposals.
- · Auditor ratification had only 77,955 votes against (0.14%) and 42,993 abstentions (0.08%).
- · Omnibus Equity Incentive Plan continuation saw 537,640 votes against (1.07%) and 1,603,137 abstentions (3.20%).
- · Company is incorporated in Wyoming with principal offices in Vancouver, British Columbia, Canada; no securities registered under Section 12(b).
- · News release dated November 10, 2026 attached as Exhibit 99.1; Report of Voting Results available on company website and EDGAR.
10-11-2026
Nuveen Farmland REIT filed an 8-K/A providing Rule 3-14 audited and pro forma financials for its September 24, 2026 acquisition of two agricultural properties (Mississippi and Illinois) totaling approximately 3,485.3 gross acres, purchased from a TIAA subsidiary for $20,633,400. The acquired properties generated $710,753 of rental revenue in FY2025 with $644,825 excess of revenue over certain operating expenses, but only $353,050 of revenue and $315,574 excess in the first half of 2026, implying a roughly 0.7% annualized decline versus FY2025 run-rate. Pro forma net income was $465 thousand for FY2025 and $229 thousand for 1H2026, with depreciation of $170 thousand and $85 thousand respectively; the acquisition was funded with $34,668,000 of gross proceeds from a September 1, 2026 private offering of 1,733,400 shares at $20.00.
- · Acquired Properties were purchased from a subsidiary of TIAA, an affiliate of the sponsor Nuveen, LLC — a related-party transaction
- · Company intends to elect REIT status beginning with taxable year ending December 31, 2026; estimated taxable operating results excluded from report
- · Future minimum rents total only $1,345 thousand, all due in 2026 ($701K) and 2027 ($644K), with nothing thereafter — short lease duration
- · Repairs and maintenance fell to $3,456 in 1H2026 from $12,873 in FY2025
- · Real estate taxes were $19,817 in 1H2026 vs $39,281 in FY2025
- · Pro forma balance sheet shows $14,036 thousand cash remaining after acquisition and $34,668 thousand total equity
- · Company is an emerging growth company and has no securities registered under Section 12(b)
- · Excluded expenses from the Rule 3-14 statements include interest, depreciation/amortization, property management fees and income taxes
10-11-2026
Intracoastal Capital LLC, together with Mitchell P. Kopin and Daniel B. Asher, filed a Schedule 13G/A reporting deemed beneficial ownership of just 65 shares of SOBR Safe common stock (issuable upon exercise of Intracoastal Warrant 1), representing approximately 0.001% of the 5,387,210 shares outstanding as of August 13, 2026. The filing explicitly excludes 860,216 shares under Warrant 2 and 820,216 shares under Warrant 3 because those warrants are not yet exercisable and carry 4.99% blocker provisions; absent those blockers, deemed beneficial ownership would total 1,680,497 shares. The negligible reported stake reflects a passive, non-control intent rather than any meaningful accumulation.
- · Reporting Persons' principal offices: Intracoastal/Kopin at 245 Palm Trail, Delray Beach, FL 33483; Asher at 1011 Lake Street, Suite 311, Oak Park, IL 60301
- · Filing made under Rule 13d-1(c)
- · Issuer formerly named TransBiotec, Inc. (name change 2012-03-02) and Imagine Media Ltd (2008-01-30)
- · Issuer business address: 6300 E. Hampden Ave., Suite C-308, Denver, CO 80222
- · Reporting Persons certified securities were not acquired for the purpose of changing or influencing control of the issuer
10-11-2026
Intracoastal Capital LLC, together with Mitchell P. Kopin and Daniel B. Asher, filed a Schedule 13G/A disclosing deemed beneficial ownership of 390,342 shares of 60 Degrees Pharmaceuticals common stock as of September 30, 2026, representing approximately 9.99% of shares outstanding. All reported shares are issuable upon exercise of Intracoastal warrants, and the 9.99% figure is capped by contractual blocker provisions; absent those blockers, beneficial ownership could have been deemed 690,685 shares. The filing is a passive-holder disclosure under Rule 13d-1(c) with no stated intent to influence control.
- · All 390,342 deemed beneficially owned shares are warrant-exercisable; no direct common shares are reported as held
- · Blocker provisions cap ownership at 9.99% (Warrants 3-4) and 4.99% (Warrants 5-9)
- · Filing is made under Rule 13d-1(c) and certifies securities were not acquired to influence control
- · Issuer is a Delaware corporation (CIK 0001946563), SIC 2834 Pharmaceutical Preparations
- · Reporting persons' principal offices: Intracoastal/Kopin in Delray Beach, FL; Asher in Oak Park, IL
- · Filing signed November 10, 2026
10-11-2026
Intracoastal Capital LLC, together with Mitchell P. Kopin and Daniel B. Asher, filed a Schedule 13G/A disclosing beneficial ownership of 62,063 shares of PowerCompute, Inc. (formerly LM Funding America, Inc.) common stock, equal to approximately 3.3% of the class. All 62,063 shares are issuable upon exercise of two Intracoastal warrants (45,162 and 16,901 shares), meaning the group holds no outright common shares — only warrant-derived exposure. The filing is a passive-investor certification (Rule 13d-1(c)) stating the securities were not acquired to influence control of the issuer.
- · Issuer changed its name from LM Funding America, Inc. to PowerCompute, Inc. (name change date listed as 20150423 in filing metadata)
- · Issuer is classified under SIC 6199 (Finance Services) and organization name '09 Crypto Assets'
- · Reporting Persons hold zero direct common shares; entire 62,063-share position is warrant-derived
- · Ownership percentage calculated on 1,794,135 outstanding shares plus 62,063 warrant shares
- · Filing made under Rule 13d-1(c) with passive-investor certification (no control intent)
- · Mr. Kopin and Intracoastal principal office: 245 Palm Trail, Delray Beach, FL 33483; Mr. Asher office: 1011 Lake Street, Suite 311, Oak Park, IL 60301
- · Issuer business address: 1200 West Platt Street, Suite 100, Tampa, FL 33606
- · Filing signed November 10, 2026
10-11-2026
Hyperscale Data, Inc. filed a Schedule 13G reporting beneficial ownership of 501,204 shares of DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) common stock, representing 9.99% of the 4,515,862 shares outstanding as of August 18, 2026. The shares are issuable upon conversion of a convertible promissory note held by Ault Lending, LLC, a wholly owned subsidiary of Hyperscale Data, and the reported figure is capped by a 9.99% beneficial ownership blocker. The filing is a passive-investor disclosure under Rule 13d-1(c), with the reporting person certifying the securities were not acquired to influence control.
- · Reporting person is Hyperscale Data, Inc. (CIK 0000896493), a Delaware corporation based in Las Vegas, NV
- · Issuer DataMeds AI, Inc. (CIK 0002030763) was formerly named Wellgistics Health, Inc. (name change 2024-10-16) and before that Danam Health, Inc. (2024-07-17)
- · Ownership chain: Ault Lending, LLC is a wholly owned subsidiary of Ault Capital Group, Inc., which is wholly owned by Hyperscale Data, Inc.
- · Filing made under Rule 13d-1(c) as a passive investor; reporting person disclaims control intent
- · Date of event triggering filing: 05/27/2026
- · Issuer business address: 3000 Bayport Drive, Suite 950, Tampa, FL 33607
- · Hyperscale Data SIC classification is Oil & Gas Filed Machinery & Equipment [3533]; issuer SIC is Wholesale-Drugs [5122]
- · SEC file number 005-96011; film number 261542050
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A disclosing beneficial ownership of 2,810,828.70 shares of Wolfspeed, Inc. common stock ($0.00125 par value), representing 5.3% of the class as of September 30, 2026. The filing is a routine passive-holder disclosure under Rule 13d-1(b), with the reporting persons certifying the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control. No prior-period ownership figure was included in this amendment, so no period-over-period change can be calculated.
- · Filing is a Schedule 13G/A amendment under Rule 13d-1(b) (passive investor exemption)
- · Reporting persons disclaim beneficial ownership beyond the Goldman Sachs Reporting Units per SEC Release No. 34-39538
- · Power of Attorney for The Goldman Sachs Group, Inc. remains in effect until July 8, 2027
- · Power of Attorney for Goldman Sachs & Co. LLC remains in effect until July 2, 2027
- · Wolfspeed is classified under SIC 3674 (Semiconductors & Related Devices) and incorporated in Delaware
- · Wolfspeed was formerly known as Cree, Inc. (name change effective 2019-08-08)
- · Joint filing agreement dated 10/08/2026
10-11-2026
Braze, Inc. filed a DEFA14A on November 10, 2026, disclosing that it intends to file a preliminary proxy statement on Schedule 14A in connection with a proposed transaction involving 'Parent' and the Company. The filing is a routine additional solicitation/proxy communication containing forward-looking statement disclaimers and boilerplate language; it discloses no financial terms, deal value, or consideration for the proposed transaction. No quantitative financial or operational metrics were provided.
- · Company intends to file a preliminary proxy statement on Schedule 14A with the SEC in connection with the proposed transaction
- · Definitive proxy statement will be delivered to shareholders as required by applicable law
- · Company's 2026 Annual Meeting Proxy Statement was filed with the SEC on May 18, 2026
- · Company and certain directors, executive officers and employees may be deemed participants in the proxy solicitation
- · Documents available free of charge at SEC's website (www.sec.gov) and Braze investor relations site (investors.braze.com)
- · Filing explicitly states it is not an offer to buy or sell securities nor a solicitation of any vote or approval
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G reporting beneficial ownership of 155,204 Class A ordinary shares of Pantages Capital Acquisition Corp (par value $0.0001), representing 5.2% of the class as of September 30, 2026. The filing was made under Rule 13d-1(b) in the ordinary course of business, with the filers certifying the securities were not acquired to influence control of the issuer. No prior-period ownership figures were disclosed, so no period-over-period comparison is possible.
- · Issuer is classified as a blank check company (SIC 6770) incorporated in Delaware, located at 221 W 9th St #859, Wilmington, DE 19801
- · CUSIP identifier for the Class A ordinary shares is G8089R100
- · Event date for the ownership position is 09/30/2026; filing date is 11/10/2026
- · Goldman Sachs & Co. LLC is a broker-dealer registered under Section 15 and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940
- · Issuer previously operated under names AIFEEX Nexus Acquisition Corp. (changed 20250311) and Shepherd Ave Capital Acquisition Corp (changed 20240717)
- · Power of Attorney for GS Group remains in effect until July 8, 2027; for Goldman Sachs & Co. LLC until July 2, 2027
- · Filing disclaims beneficial ownership of securities held in client accounts and certain investment entities per SEC Release No. 34-39538
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G reporting beneficial ownership of 1,209,826 Class A ordinary shares of Disciplined Growth Acquisition Corp (a blank-check company), representing 7.2% of the class as of September 30, 2026. The filing is a routine passive-investor disclosure under Rule 13d-1(b), with the filers certifying the securities were acquired in the ordinary course of business and not for the purpose of influencing control. No change in ownership versus a prior period is disclosed in this filing.
- · Reporting persons hold sole voting power and sole dispositive power over all 1,209,826 shares (0 shared voting/dispositive power reported)
- · Filing made under Rule 13d-1(b) as a passive investor; filers certify securities not held to change or influence control
- · Issuer is a blank-check company (SIC 6770) incorporated in E9 (Cayman Islands) with CUSIP G2775W101
- · Event date of ownership snapshot: 09/30/2026; filing date 11/10/2026
- · Power of Attorney for GS Group valid until July 8, 2027; for Goldman Sachs & Co. LLC until July 2, 2027
- · Highbridge Capital Management, LLC referenced in Item 7 information exhibit
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting beneficial ownership of 28,444,391.52 ordinary shares of IREN Ltd, representing 7.2% of the class as of September 30, 2026. The filing is a routine passive-investor disclosure under Rule 13d-1(b), with the filers certifying the securities were acquired in the ordinary course of business and not for the purpose of influencing control. No prior-period ownership figure is disclosed in this amendment, so no period-over-period change can be calculated.
- · Filing is an amendment (13G/A) to a previously filed Schedule 13G; no prior ownership percentage is disclosed for comparison
- · Goldman Sachs & Co. LLC is a broker-dealer registered under Section 15 and an investment adviser under Section 203 of the Investment Advisers Act of 1940
- · Filing reflects only Goldman Sachs Reporting Units; securities of disaggregated operating units are excluded per SEC Release No. 34-39538
- · Power of Attorney for GS Group valid until July 8, 2027; for Goldman Sachs & Co. LLC until July 2, 2027
- · IREN Ltd is incorporated outside the US (Sydney, NSW, Australia headquarters) with fiscal year end June 30
- · CUSIP: Q4982L109; SEC file number 005-93477
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G disclosing beneficial ownership of 962,965 Class A ordinary shares of Digital Asset Acquisition Corp. (par value $0.0001), representing 5.6% of the class as of September 30, 2026. The filing was made under Rule 13d-1(b) in the ordinary course of business, with the filers certifying the securities were not acquired to influence control of the issuer. No prior-period ownership figures were disclosed, so no period-over-period comparison is possible.
- · Filing made pursuant to Rule 13d-1(b) as a passive institutional holder
- · Sole voting power and sole dispositive power each reported at 962,965 shares for both reporting persons
- · Goldman Sachs & Co. LLC is a broker-dealer registered under Section 15 and an investment adviser under Section 203 of the Investment Advisers Act of 1940
- · CUSIP identifier for the Class A ordinary shares is G2868C103
- · Issuer is classified under SIC 6022 (State Commercial Banks) and incorporated in E9 (Cayman Islands)
- · Power of Attorney for GS Group valid until July 8, 2027; for Goldman Sachs & Co. LLC until July 2, 2027
- · Filing reflects only securities of Goldman Sachs Reporting Units; certain client-account holdings are disaggregated per SEC Release No. 34-39538
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A amendment reporting beneficial ownership of Esperion Therapeutics common stock (par value $0.001 per share) as of September 30, 2026, under Rule 13d-1(b). The cover page reports 0.00 shares and 0.0% ownership across all reporting persons, indicating no reportable beneficial ownership position. The filing is a routine passive-investor disclosure with no change-of-control intent, accompanied by a joint filing agreement and powers of attorney dated July 2026.
- · Filing is a Schedule 13G/A amendment under Rule 13d-1(b) (passive institutional investor)
- · Event date (as of) for ownership: 09/30/2026; filing date 11/10/2026
- · Esperion Therapeutics is classified under SIC 2834 (Pharmaceutical Preparations), incorporated in Delaware, headquartered in Ann Arbor, MI
- · Goldman Sachs & Co. LLC is a broker-dealer registered under Section 15 and an investment adviser under Section 203 of the Investment Advisers Act of 1940
- · Filing disclaims beneficial ownership of client-account securities per SEC Release No. 34-39538
- · Powers of attorney remain in effect until July 8, 2027 (GS Group) and July 2, 2027 (Goldman Sachs & Co. LLC)
- · Joint filing agreement dated 10/08/2026
10-11-2026
Goldman Sachs Group Inc. and its subsidiary Goldman Sachs & Co. LLC filed a Schedule 13G/A disclosing beneficial ownership of 1,219,009 Class A ordinary shares of GigCapital9 Corp. (a blank-check company), representing 4.7% of the class as of September 30, 2026. The filing is a routine passive-investor disclosure under Rule 13d-1(b), with Goldman certifying the securities were acquired in the ordinary course of business and not for the purpose of influencing control. No change in share count versus a prior filing is disclosed in the text, so period-over-period movement cannot be determined from this excerpt.
- · Sole voting power reported as 0.00; shared voting power 1,219,009 shares; sole dispositive power 0.00; shared dispositive power 1,219,009 shares
- · Filing made under Rule 13d-1(b) as a passive investor; Goldman disclaims control intent
- · Issuer is a blank-check company (SIC 6770) incorporated in E9 (Cayman Islands), CUSIP G3865B114
- · Event date (as of) September 30, 2026; filing date November 10, 2026
- · Power of Attorney for GS Group valid until July 8, 2027; for Goldman Sachs & Co. LLC until July 2, 2027
- · Exhibit 99.3 notes ownership is disaggregated per SEC Release No. 34-39538 and excludes certain client-account holdings
10-11-2026
Goldman Sachs Group Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G reporting beneficial ownership of 11,214,076.62 Liberty Global Class A common shares (6.3% of the class) as of September 30, 2026, with sole voting power over 11,213,836.62 shares and sole dispositive power over 11,214,076.62 shares. The filing is a routine passive-investor disclosure under Rule 13d-1(b), certifying the securities were acquired in the ordinary course of business and not for the purpose of influencing control. No change from a prior period is disclosed in this filing, so no period-over-period comparison is available.
- · Filing is made under Rule 13d-1(b) as a passive investor disclosure, not an activist position
- · Goldman Sachs & Co. LLC is a broker-dealer registered under Section 15 and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940
- · Ownership as of event date 09/30/2026; filing dated 11/10/2026
- · Liberty Global is classified under SIC 4841 (Cable & Other Pay Television Services) and is incorporated in Hamilton, Bermuda
- · Power of Attorney for GS Group remains in effect until July 8, 2027; for Goldman Sachs & Co. LLC until July 2, 2027
- · Filing disclaims beneficial ownership of securities held in certain client accounts and investment entities per SEC Release No. 34-39538
31-03-2026
Brookfield Business Partners filed its 2025 20-F reporting revenues of $27,457M, down 32.4% YoY from $40,620M (which itself fell 26.2% from $55,068M in 2023), driven largely by dispositions and deconsolidation. Net income fell 56.8% to $387M from $895M, and net income attributable to Unitholders swung to a $43M profit from a $109M loss, while Adjusted EBITDA declined 6.1% to $2,409M from $2,565M. The company remained active on M&A, completing the $1.3B Antylia Scientific acquisition, the $2.6B First National Financial privatization, and agreeing to acquire Fosber for ~$950M, while total assets were roughly flat at $75,761M versus $75,474M.
- · Segment revenues 2025: Industrials $14,936M, Business services $9,368M, Infrastructure services $3,153M
- · Segment assets at Dec 31, 2025: Industrials $29,914M, Business services $28,578M, Infrastructure services $16,270M, Corporate $999M
- · Geographic revenues 2025: USA $8,797M, Europe $4,846M, Australia $4,130M, Brazil $2,605M, UK $2,149M, Canada $1,754M, Mexico $1,278M, Other $1,898M
- · Basic and diluted loss per limited partner unit was $(0.30) in 2025 vs $(0.50) in 2024 and $6.49 in 2023
- · Q3 2025 net loss of $(122)M and Q4 2025 net income of $118M; Q3 2024 net income was $1,735M
- · Interest expense, net rose to $(3,139)M in 2025 from $(3,104)M in 2024
- · Interest of others in operating subsidiaries fell to $9,120M at Dec 31, 2025 from $11,451M at Dec 31, 2024
- · Goodwill increased $1,071M to $13,310M; property, plant and equipment declined $2,219M to $11,013M
- · Offshore oil services FPSO sale expected to close in first half of 2026; did not meet held-for-sale criteria at Dec 31, 2025
- · Fosber acquisition subject to customary regulatory approvals, expected to close in first half of 2026
10-11-2026
Bridges Investment Management Inc filed its Q3 2026 13F-HR holdings report (period ended September 30, 2026), disclosing 923 total positions with an aggregate reported value of approximately $8.46 billion. The portfolio is heavily concentrated in mega-cap technology and blue-chip names, with Alphabet (Class A and C combined across accounts), Apple, Amazon, Broadcom, Berkshire Hathaway, BlackRock, AutoZone, Carlisle, Cintas, and Casey's among the largest disclosed positions. The filing is a routine quarterly institutional holdings disclosure and does not reflect a corporate event at any issuer.
- · Filing is for the quarter ended September 30, 2026, filed November 10, 2026 (accession 0001007295-26-000012).
- · Filer is Bridges Investment Management Inc of Omaha, Nebraska (SEC file 028-06375).
- · Total portfolio value reported: $8,460,750,780 across 923 holdings.
- · Two positions are carried at zero value: Cannabis Science Inc (36,500 shares) and CGTV Media Group (20,000 shares).
- · Holdings are split across SOLE, DFND, and DFND 01 account designations, with DFND 01 generally the largest account.
- · No period-over-period comparison data is included in this filing.
10-11-2026
Atour Lifestyle Holdings filed a Form 6-K on November 10, 2026, furnishing two press releases: its unaudited third quarter 2026 financial results and the announcement of a cash dividend. The filing itself contains only cover-page and signature information, with the substantive financial figures and dividend amount residing in Exhibits 99.1 and 99.2, which were not included in the provided text. No period-over-period metrics can be computed from the filing body.
- · Filing is a Form 6-K under Rule 13a-16/15d-16 of the Securities Exchange Act of 1934 for the month of November 2026
- · Commission File Number: 001-40540
- · Registrant files annual reports under Form 20-F
- · Principal executive office: 1st floor, Wuzhong Building, 618 Wuzhong Road, Minhang District, Shanghai, 201103, People's Republic of China
- · Exhibit 99.1: Press Release — Third Quarter 2026 Unaudited Financial Results
- · Exhibit 99.2: Press Release — Cash Dividend announcement
- · Signed by Haijun Wang, Chairman of the Board of Directors and Chief Executive Officer, dated November 10, 2026
- · No financial figures, dividend per share amount, or period comparisons are present in the filing body itself
10-11-2026
Werewolf Therapeutics filed a Rule 425 communication containing Ambros Therapeutics' November 2026 Analyst Day presentation detailing their proposed reverse triangular merger. The combined company is anticipated to be valued at ~$697.5M at closing, with Ambros implied at $500M and Werewolf at $47.5M, alongside a concurrent $150M PIPE co-led by RA Capital Management and Janus Henderson Investors. Pro forma ownership splits ~72.0% Ambros, ~21.6% PIPE investors, and only ~6.4% Werewolf, with closing expected in Q4 2026; however, the transaction remains subject to stockholder approvals and closing conditions, and the lead asset neridronate has no FDA approval and depends on a single Phase 3 (CRPS-RISE) that may not stop early for efficacy.
- · Neridronate holds FDA Breakthrough Therapy, Fast Track, and Orphan Drug Designations
- · FDA aligned on a single pivotal Phase 3 (CRPS-RISE) and on including an interim analysis (October 2026)
- · Neridronate approved in Italy for CRPS, but Italian commercialization rights are not held by Ambros
- · Ambros received Notice of Allowance for neridronate method-of-use patent in March 2026, potentially extending exclusivity to 2045
- · First patient dosed in CRPS-RISE in June 2026; trial currently recruiting
- · Werewolf's legacy pipeline is addressed through a CVR
- · Combined company to be renamed Ambros Therapeutics, Inc. and trade on Nasdaq under ticker 'AMBX'
- · CRPS-1 typical onset age 40-60, more frequent in women; no FDA-approved therapies exist
- · Interim analysis may not meet prespecified statistical threshold to stop early for efficacy, requiring trial to continue to final analysis
10-11-2026
Quantum Space, LLC held an Analyst and Investor Day on November 9, 2026, disclosed via a Form 425 filing by IPFX PubCo, Inc. (Commission File No. 333-299286-01), indicating a pending going-public transaction — Chairman Kam Ghaffarian's third public company after X-energy and Intuitive Machines. CEO Jim Bridenstine (former NASA Administrator) and President/co-founder Kerry Wisnosky pitched high-energy, refuelable satellites for national security and cislunar space, with CFO Adarsh Parekh noting he previously helped raise well over $200 million at Sidus Space. The transcript corrected earlier statements: first vehicle Prime's launch moved from 'June or July 2027'/'Q2 2027' to the 'second half of 2027,' and NASA payload deliveries to the moon cut from 'three' to 'two' — a schedule slip and scope reduction, though no financial results, revenue, or backlog figures were disclosed.
- · Prime launch timing corrected from 'June or July 2027'/'Q2 2027' to 'second half of 2027'
- · NASA payload deliveries to the moon corrected from three to two
- · Company founded in 2021 by Kerry Wisnosky and Dr. Kam Ghaffarian
- · Chairman Kam Ghaffarian's third public company (after X-energy and Intuitive Machines)
- · Satellites claimed to have largest fuel tanks in class, refuelable and able to refuel others
- · Contracts with Air Force Research Lab for single-fuel chemical/electric propulsion
- · No revenue, backlog, contract value, or financial statements disclosed in the transcript
- · Filing is a Rule 425 communication deemed filed under Rule 14a-12, signaling a pending business combination
10-11-2026
Quantum Space, via a Rule 425 filing by Inflection Point Acquisition Corp. VI, released a transcript of its November 9, 2026 Analyst and Investor Day, positioning itself as a high-energy satellite maker targeting national security, commercial, and civil space markets. The company corrected prior statements, pushing the first launch of its Prime vehicle from 'June or July 2027'/'Q2 2027' to the 'second half of 2027' and reducing NASA lunar payloads from three to two. Management highlighted differentiated refuelable, dual chemical/electric propulsion satellites and a planned SPAC listing, but offered no financial figures, revenue guidance, or order backlog, and the launch timeline slipped.
- · No revenue, EBITDA, backlog, or financial guidance figures were disclosed in the transcript
- · Prime launch timing corrected from 'June or July 2027'/'Q2 2027' to 'second half of 2027'
- · NASA lunar payload count corrected from three to two
- · Company founded in 2021; Kam Ghaffarian's third space company to go public after X-energy and Intuitive Machines
- · Satellites designed to be refuelable and to refuel others, using storable/transferable hydrazine
- · AFRL contracts in place to develop single-fuel chemical and electric propulsion
- · CFO previously CFO of Sidus Space and at Terran Orbital (sold to Lockheed Martin)
10-11-2026
Abony Acquisition Corp. I filed its first 10-Q for Q3 2026, reporting net income of $1,934,859 for the three months and $4,323,596 for the nine months ended September 30, 2026, driven entirely by $2,127,836 and $4,999,382 of interest earned on the $234,999,382 Trust Account. However, operating losses widened as formation and general/administrative costs totaled $192,977 for the quarter and $675,786 year-to-date, and the company posted a shareholders' deficit of $7,114,755 (up sharply from $74,715 at December 31, 2025) largely due to $16,543,031 of accretion of Class A shares to redemption value.
- · Class A ordinary shares subject to possible redemption: 23,000,000 shares at approximately $10.22 per share, totaling $234,999,382
- · Net cash used in operating activities of $626,870 for the nine months
- · Repayment of promissory note – related party of $302,954
- · Payment of offering costs of $400,356
- · Deferred legal fees of $118,044 and accrued offering costs of $75,000 at September 30, 2026
- · Basic weighted average Class A shares outstanding of 23,695,000 (Q3) and 19,268,462 (nine months)
- · Fair value of Public Warrants at issuance of $2,568,333
- · Allocated transaction costs to Public Warrants and Private Placement Units of $167,942
- · Accretion of Class A shares to redemption amount of $2,127,836 in Q3 and $2,043,160 in Q2 2026
- · No preference shares issued or outstanding; 5,000,000 authorized
10-11-2026
Focus Universal reported Q3 2026 total revenue of $802,428 versus just $28,689 in Q3 2025, driven entirely by new rental revenue of $789,128 as the company pivots into property ownership. However, total costs and operating expenses jumped 62% to $1,958,312, keeping the operating loss roughly flat at $(1,155,884) and net loss widening to $(1,389,425) from $(1,166,375) as interest expense of $(233,028) replaced prior interest income. For the nine months, revenue rose to $1,525,571 from $254,274 while net loss to common stockholders deepened to $(4,381,127) from $(3,923,401).
- · Basic net loss per share improved to $(1.80) in Q3 2026 from $(6.34) in Q3 2025, and to $(8.24) from $(21.62) for nine months, largely due to share count expansion (weighted average shares 770,216 vs 183,937).
- · Other revenue declined 66.8% for nine months to $84,493 from $254,274, and fell to $13,300 in Q3 from $28,689.
- · Research and development rose 68.1% to $484,185 in Q3 2026 from $288,078, while G&A fell 19.3% to $356,163 from $441,414.
- · Property operating expenses of $400,655 and depreciation/amortization of $235,838 are new Q3 costs tied to the rental segment.
- · Cash fell 44% to $4,440,231 from $7,934,958, with $6,656,391 spent on property/equipment purchases during nine months.
- · Total liabilities surged to $11,956,040 from $366,471, including a $10,839,154 non-current loan tied to an $11,050,000 building acquisition loan.
- · Series B preferred stock was fully converted/redeemed (0 shares outstanding vs 7,263), with $5,127,200 converted to common and $961,860 redeemed.
- · Financing raised $3,720,676 from stock issuance/warrant exercises and $3,547,348 from pre-funded units.
- · Operating cash burn improved to $2,742,684 used from $3,709,104 used year-over-year.
- · Accumulated deficit deepened to $35,404,538 from $31,023,411.
10-11-2026
TEN Holdings, Inc. (Nasdaq: XHLD) closed a registered direct offering of 3,389,831 shares of common stock at $0.59 per share, raising gross proceeds of approximately $2.0 million before expenses, with net proceeds earmarked for working capital and general corporate purposes. The offering was made under an S-3 registration statement (File No. 333-299485) filed October 16, 2026 and declared effective October 26, 2026. The raise is small relative to the company's stated growth ambitions, and the $0.59 per-share pricing implies a low absolute share price; the filing contains no period-over-period financial metrics or operating results.
- · Offering was conducted under an effective Form S-3 registration statement (File No. 333-299485), initially filed October 16, 2026 and declared effective October 26, 2026
- · Company intends to use net proceeds for working capital and general corporate purposes
- · TEN Holdings describes itself as a New York-based technology company providing enterprise software for digital experiences, supporting up to 50,000 concurrent attendees
- · Product roadmap includes marketing automation, CRM integrations, advanced engagement analytics, AI-powered capabilities, and content management, all subject to ongoing development with no assurance of timing or availability
- · Company states its strategy centers on expanding SaaS offerings and increasing recurring revenue opportunities
- · Investor relations contact is Skyline Corporate Communications Group, LLC (Scott Powell, President), phone (646) 893-5835
10-11-2026
Godfrey Financial Associates, Inc. filed its Q3 2026 13F-HR disclosing 1,058 total holdings valued at $124,559,601 as of September 30, 2026. The portfolio is heavily concentrated in mega-cap technology, with Arista Networks ($1.53M), Alphabet Class A ($1.53M), Dell Technologies ($1.77M), Amazon ($1.17M) and Apple ($1.11M) among the largest positions, alongside sizable ETF allocations. The filing reflects a diversified, buy-and-hold institutional book spanning equities, ADRs and ETFs, with no period-over-period comparison data provided in this disclosure.
- · Total reported portfolio value: $124,559,601 across 1,058 holdings as of 09-30-2026
- · Filing submitted November 10, 2026 for period ending September 30, 2026
- · Filer CIK 0002097943; SEC File Number 028-26155; CRD 000126189; SEC 801-78531
- · All positions reported as sole voting/discretionary authority (no shared or none disclosed)
- · Largest single position is Dell Technologies at $1,773,621 (3,297 shares)
- · Two separate Constellation Energy Corp lots reported: $31,244 (123 shares) and $31,498 (124 shares)
- · Notable micro-positions include AMC Entertainment ($6, 2 shares), Canopy Growth ($9, 10 shares) and Beyond Meat ($17, 2 shares)
- · Significant ETF allocation spanning iShares, Dimensional, Capital Group, American Century, ARK, Amplify, ALPS, BondBloxx and Xtrackers families
- · No period-over-period holdings comparison data included in this filing
10-11-2026
BHAV Acquisition Corp, a Cayman Islands SPAC, entered into a Business Combination Agreement on November 3, 2026 with Nemi Corp. (a Texas corporation) and its subsidiary BNC Motors Pvt. Ltd (an Indian company), under which BHAV will merge into a Pubco structure and become a publicly traded company. Nemi shareholders will receive 40,000,000 newly issued Pubco shares valued at an aggregate $400 million, with founder/CEO Anirudh Ravi Narayanan and ARN Advisory Partners receiving super-voting Class B shares (10 votes per share) while public holders receive one-vote Class A shares. The deal includes customary no-solicitation covenants and a fiduciary-out provision allowing BHAV's board to change its recommendation subject to a five-business-day notice period.
- · Each BHAV Class B ordinary share converts into one Class A ordinary share immediately prior to the First Effective Time
- · Each BHAV share right converts into one-fourth (1/4) of one BHAV Class A Ordinary Share, then into Pubco Class A Common Stock
- · Devanur Sponsor Shares allocated to CEO Giri Devanur convert into Pubco Class B Common Stock rather than Class A
- · Pubco Class B shares carry 10 votes per share vs. one vote for Class A, giving founder holders outsized control
- · Nemi Equity Awards convert into Pubco Class A Common Stock awards based on an Exchange Ratio
- · Nemi may consummate Permitted Financing Securities (SAFEs, convertible notes/debentures) that convert into Pubco Class A Common Stock at closing
- · Representations and warranties do not survive Closing; no indemnification rights for breach
- · BHAV and Nemi are subject to no-solicitation covenants prohibiting competing alternative transactions
- · BHAV listed on Nasdaq under symbols BHAVU (units), BHAV (Class A shares), BHAVR (rights)
- · BHAV is an emerging growth company; principal executive offices listed at Piscataway, NJ
10-11-2026
Vawter Financial, Ltd. filed its Q3 2026 13F-HR disclosing 130 total holdings valued at $268,905,593 as of September 30, 2026. The portfolio is heavily ETF-weighted, with the largest positions being JPMorgan Active Bond ETF ($19.4M), Vanguard Morningstar Small Cap Growth ($17.3M), Vanguard Total International Bond ETF ($15.0M), Vanguard Short-Term Bond ($14.3M), and Dimensional EM Core Equity ($13.3M). Individual equity exposure is comparatively modest, led by Apple ($3.4M), Berkshire Hathaway Class A ($3.0M), and iShares Core S&P 500 ($8.0M).
- · All 130 positions are held in sole voting authority with zero shared or discretionary-other voting, indicating fully managed in-house portfolio
- · Portfolio is predominantly ETF-based, with bond and international equity ETFs comprising the bulk of top holdings
- · Berkshire Hathaway Class A position of just 4 shares is valued at $2,988,020
- · Smallest disclosed positions include Banco Santander ADR ($159,045) and Procter & Gamble ($200,922)
- · Filing signed by Jacqueline Washburn, Chief Compliance Officer, dated 11-09-2026
- · Filer is an Ohio-based entity (Columbus, OH), SEC File Number 028-23274
10-11-2026
Synchrony Financial filed an 8-K on November 10, 2026 furnishing its monthly charge-off and delinquency statistics for the thirteen months ended October 31, 2026 (Exhibit 99.1) under Regulation FD. The filing contains no financial figures or performance data in the body text itself, only a commitment to continue furnishing these credit metrics monthly, with quarter-end months disclosed alongside quarterly earnings. No period-over-period comparisons can be assessed from this filing as the underlying statistics are in the exhibit, which was not provided.
- · Exhibit 99.1 contains monthly charge-off and delinquency statistics for each of the thirteen months ended October 31, 2026
- · Company intends to furnish these statistics monthly, with quarter-end month statistics released contemporaneously with quarterly financial results
- · Information furnished under Item 7.01 is not deemed 'filed' for Section 18 purposes and not incorporated by reference
- · Common stock, Series A and Series B preferred depositary shares (each 1/40th interest) all listed on the NYSE
- · Registrant is not an emerging growth company
10-11-2026
Cornerstone Capital, Inc. filed its Q3 2026 13F-HR disclosing $1,088,938,091 in institutional holdings across 109 positions as of September 30, 2026. The portfolio is heavily concentrated in mega-cap technology, with Microsoft ($59.7M), Alphabet Class A ($57.3M), Amazon ($44.7M), Visa ($47.3M), and Amphenol ($42.9M) among the largest positions. However, the book also holds many small positions (e.g., Enovix at $80,518, Joby Aviation at $118,882, and a single Berkshire Class A share at $747,005), reflecting a long-tail allocation strategy.
- · All 109 positions are held solely (SOLE voting authority) with zero shared or no-vote allocations.
- · Filing was signed by N Brigette Guldbech, Chief Compliance Officer, on 11-09-2026.
- · Filer's former name was Petersen Flynn & Dinsmore Inc, changed 2000-05-18; SEC file number 028-05773.
- · Portfolio includes a single Berkshire Hathaway Class A share valued at $747,005.
- · Notable small/venture-style positions include Enovix ($80,518), Joby Aviation ($118,882), and SpaceX Class A ($286,634).
- · Large ETF/index allocations include SPDR S&P 500 ETF Trust ($28.4M), iShares MSCI India ETF ($6.9M), and Select Sector SPDR Utilities ($15.8M).
- · No period-over-period comparison data is provided in this 13F filing (holdings snapshot only).
10-11-2026
Embraer reported 3Q26 revenue of US$2,347.2 million, an all-time high for a third quarter and up 17% YoY, with Adjusted EBIT of US$254.8 million (10.9% margin vs 8.6% in 3Q25) and record firm backlog of US$35.7 billion (+14% YoY). However, Adjusted net income fell to US$73.6 million from US$84.3 million a year ago on higher net financial and tax expenses, and the Others segment revenue dropped 44% YoY to US$18 million. Management raised full-year revenue guidance to US$8.4-8.6 billion and free cash flow guidance to US$700 million or higher, while keeping delivery and EBIT margin targets unchanged.
- · Adjusted EBITDA fell to US$317.1 million (13.5% margin) in 3Q26 from US$355.6 million (15.9%) in 2Q26, though up from US$236.3 million (11.8%) in 3Q25
- · Eve net cash worsened US$(61.0) million QoQ to US$29.9 million and is down US$(212.6) million YoY from US$242.5 million
- · Eve free cash flow was negative US$(55.0) million in 3Q26
- · Others segment Adjusted EBIT context: revenue fell 44% YoY to US$18 million on lower agricultural aviation deliveries and weaker Tempest/Electronic Equipment sales
- · Working capital improved by US$(654.9) million in 3Q26, driven by contract liabilities (+US$451.1 million) and other payables (+US$240.9 million)
- · Embraer stand-alone gross debt reduced US$(174.0) million QoQ to US$1,977.9 million; average loan maturity 8.7 years, 95% long-term
- · Cost of USD-denominated loans fell to 5.09% from 5.14% QoQ; euro-denominated loans unchanged at 3.90%
- · Net debt/Adjusted EBITDA LTM improved to 0.4x net cash in 3Q26 from (0.5)x in 3Q25
- · Effective November 16, 2026, Embraer will change its ADS ratio from 4 common shares to 1 common share
- · Market cap on September 30, 2026: R$63.3 billion / US$12.2 billion; 3-month ADTV R$509 million / US$81 million
- · 2026 guidance: revenue raised to US$8.4-8.6B (from US$8.2-8.5B); FCF raised to US$700M+ (from US$400M+); EBIT margin and delivery ranges unchanged
- · Income tax expense of US$10.8 million in 3Q26 vs a US$22.0 million tax credit in 3Q25
- · Financial expense rose to US$(218.9) million in 3Q26 from US$(99.1) million in 3Q25, partly on LTI share mark-to-market
10-11-2026
HIVE Digital reported Q2 FY2027 revenue of $84.9 million, up 7.3% sequentially but down 2.7% year over year, as HPC revenue surged 70.7% YoY to $8.8 million while digital currency mining revenue fell 7.4% YoY to $76.0 million. Gross operating margin improved to $30.2 million (35.6% of revenue) and Adjusted EBITDA rose 85% sequentially to $24.8 million, however the company posted a GAAP net loss of $78.7 million driven by $54.9 million of depreciation and a $31.2 million non-cash impairment of mining equipment. HIVE ended the quarter with $139.0 million in cash and $22.6 million in digital currencies, and reported approximately $40 million live GPU Cloud ARR against approximately $185 million in contracted ARR.
- · Average network difficulty declined to approximately 128 trillion from 135 trillion in Q1 FY2027
- · HIVE received 1,070 Bitcoin in rewards vs 1,004 in the preceding quarter
- · SG&A rose to $10.7M from $9.0M sequentially and $7.8M in Q2 FY2026, driven by the Merritt facility lease for HPC expansion
- · ATM program: 13,698,085 shares issued at average price of $3.15 (C$4.38) for gross proceeds of approximately $43.2M, with $1.3M cash commission
- · Contracted ARR includes capacity not yet in service and is not equivalent to recognized revenue
- · The 100 MW Yguazú PPA is currently unallocated, providing flexibility across hashrate, AI and HPC workloads
- · Earnings call scheduled for November 10, 2026 at 8:00 a.m. ET
- · Company cites US election-related rhetoric and mid-term political shifts as potential constraints on new US data center development
- · Ontario released a data center playbook in August 2026 and the Premier's office committed to approving new data centers sooner
10-11-2026
Pyxus International and its wholly-owned subsidiary Pyxus Holdings launched a private exchange offer for any and all of the Issuer's outstanding 8.50% Senior Secured Notes due 2027, offering a mix of common stock (priced at $3.25/share) and new floating rate senior secured notes per $1,000 principal. Early tenders (by Nov 24, 2026) receive $344.37 in equity value plus $675.90 in new notes, while later tenders (by Dec 10, 2026) receive $327.15 in equity plus $642.11 in new notes. Concurrently, the Company is soliciting consents to strip most restrictive covenants, eliminate the change-of-control repurchase obligation, subordinate the Existing Notes, eliminate certain events of default, and release all collateral — a broad erosion of existing noteholder protections that signals a liability-management/refinancing exercise.
- · Early Tender Time is 5:00 p.m. New York City time on November 24, 2026
- · Exchange Offer and Consent Solicitation expire at 5:00 p.m. New York City time on December 10, 2026, unless extended or terminated
- · Consent Solicitation seeks to (i) eliminate most restrictive and certain affirmative covenants, (ii) eliminate the change of control repurchase obligation, (iii) subordinate Existing Notes and guarantees to existing and future senior indebtedness including the Exchange Notes and ABL credit agreement, (iv) eliminate certain events of default, and (v) release all collateral securing the Existing Notes
- · Exchange Notes to be issued by Pyxus Holdings and guaranteed by specified parent and subsidiary guarantors
- · Press release filed as Exhibit 99.1; cover page Interactive Data File as Exhibit 104
- · Company address: 6001 Hospitality Court, Suite 100, Morrisville, North Carolina 27560-2009; phone (919) 379-4300
- · Commission file number 000-25734; IRS Employer ID 85-2386250; incorporated in Virginia
- · No securities registered pursuant to Section 12(b) of the Act
- · Forward-looking statements reference Risk Factors in Form 10-K for fiscal year ended March 31, 2026
10-11-2026
Embraer reported its best-ever Q3 revenue of US$2.3 bn (+17% YoY from US$2,004 m), with revenue growth across all four divisions and adjusted EBIT margin expanding to 10.9% (from 8.6%). Backlog hit a record US$35.7 bn (8th consecutive all-time high, +14% YoY), and the company raised 2026 guidance for revenue to US$8.4-8.6 bn and FCF to >US$700 m. However, adjusted net income declined to US$74 m (3.1% margin) from US$84 m (4.2%) a year earlier, and 9M26 commercial deliveries of 52 aircraft tracked at only 63% of guidance mid-point versus 70% for executive aviation, signaling back-half loading risk.
- · Book-to-bill LTM: Consolidated 1.5x; Commercial Aviation 1.2x; Executive Aviation 1.4x; Defense & Security 2.9x; Services & Support 1.3x
- · Backlog mix 3Q26: Commercial Aviation US$15.8 bn, Executive Aviation US$8.2 bn, Defense & Security US$6.1 bn, Services & Support US$5.6 bn
- · 3Q26 adjusted EBIT margin ex U.S. tariffs and tax credits: 16.0% vs 14.7% in 3Q25
- · Defense & Security adj. EBIT margin 17.0% ex tariffs/tax credits vs 14.1% prior year
- · Services & Support EBIT US$108 m (+US$40 m YoY), margin 17.0% (+330bp)
- · Commercial Aviation EBIT US$17 m (+US$9 m YoY), margin 2.4% (+110bp)
- · Executive Aviation EBIT US$105 m (+US$34 m YoY), margin 16.0% (+390bp)
- · Defense & Security EBIT US$54 m (+US$18 m YoY), margin 15.7% (+280bp)
- · 2026 guidance: Commercial deliveries 80-85, Executive deliveries 160-170, Adj. EBIT margin 10.0%-10.6%
- · 9M26 adjusted EBITDA US$816 m vs US$396 m 5Y average; adjusted EBIT US$646 m vs US$251 m 5Y average
- · 9M26 adjusted FCF at 6.8% of mid-point revenue vs -4.0% 5Y average
- · Net cash without Eve / Adj. EBITDA: 0.4x in 3Q26 vs 0.1x in 3Q25; gross debt US$1,115 m with 8.7-year average maturity and 5.1% average cost
- · Eve prototype: 73 total flights, 3h 06min total flight time, 170 points validated, 91% of flight campaign complete
- · Shareholder remuneration: 2Q26 IoE R$200.0 m (R$0.28/share, US$0.22/ADS), 3Q26 IoE R$154.0 m (R$0.22/share, US$0.17/ADS)
- · Farnborough drove 28 E2 firm orders from Abra Group, Binter and Luxair; ANA ordered 8 additional E190-E2 bringing total to 23 aircraft
- · Colombia ordered 2 KC-390 Millennium aircraft
10-11-2026
On Holding AG filed a Form 6-K on November 10, 2026, furnishing a press release and Management's Discussion and Analysis covering the third quarter ended September 30, 2026. The filing itself contains only cover-page, signature, incorporation-by[redacted], and exhibit-index information; the substantive financial figures reside in Exhibits 99.1 and 99.2, which are not reproduced in the provided text. No quantitative results, period-over-period comparisons, or segment performance data can be verified from the filing body as presented.
- · Filing is a Form 6-K for the month of November 2026 under Commission File Number 001-40795
- · Report covers the third quarter ended September 30, 2026
- · Exhibit 99.1 is a press release dated November 10, 2026
- · Exhibit 99.2 is Management's Discussion and Analysis of Financial Condition and Results of Operations for Q3 2026
- · Report is incorporated by reference into Form F-3 (Registration No. 333-291559) and Form S-8 (Registration Nos. 333-259533, 333-268853 and 333-293976)
- · Principal executive office: Förrlibuckstrasse 190, 8005 Zurich, Switzerland; Tel +41 44 225 1555
- · Registrant files annual reports under Form 20-F
- · Signed by Frank Sluis, Chief Financial Officer, dated November 10, 2026
- · No actual revenue, margin, or growth figures are present in the filing text provided — financials are in the exhibits
10-11-2026
Siena Capital Partners GP, LLC filed its Q3 2026 13F-HR disclosing 101 holdings valued at $425,328,122 as of September 30, 2026. The portfolio is overwhelmingly concentrated in community and regional bank stocks, with the largest positions being West Coast Community Bancorp ($17.8M), Plumas Bancorp ($14.6M), Southern BancShares NC ($14.3M), Exchange Bank/Santa Rosa ($10.9M), and Timberland Bancorp ($10.3M). The filing is a routine quarterly holdings disclosure and contains no period-over-period comparison data, so no growth or decline metrics can be derived.
- · Filing is a 13F-HR Holdings Report for the period ending 09-30-2026, filed 11-10-2026 under SEC File Number 028-17647
- · All 101 positions are held in SOLE voting authority with no shared or discretionary split reported
- · Portfolio is almost entirely community/regional bank equities, indicating a sector-concentrated strategy
- · Smallest reported positions include Northeast Indiana Bancorp ($223,115), Citizens Bancorp Investment ($216,289), and Somerset Trust Holding ($344,776)
- · First Citizens BancShares appears in two share classes: Class A (4,344 shares, $8.9M) and a second class (876 shares, $1.5M)
- · Filer was formerly named Siena Capital Management, LLC (name changed 01-17-2017) and is based in Evanston, IL
10-11-2026
Mirum Pharmaceuticals announced that the Phase 3 AZURE-4 study of brelovitug met its primary endpoint in chronic hepatitis delta virus (HDV), with 59% of patients on 300 mg QW and 44% on 900 mg Q4W achieving the combined virologic response and ALT normalization endpoint versus 0% in the delayed-treatment arm (p≤0.0001). The company also highlighted AASLD data showing deepening viral suppression and ALT normalization with longer treatment. However, the 900 mg Q4W arm's combined endpoint rate (44%) was notably lower than the 300 mg QW arm (59%), and the drug remains investigational with BLA submission not planned until H1 2027 and potential U.S. launch only in Q4 2027, if approved.
- · AZURE-4 enrolled 113 treatment-naïve patients randomized 2:1:1; 53% had cirrhosis, ~half had baseline HDV RNA >6 log10 IU/mL, mean baseline ALT was 122 U/L
- · AZURE-4 virologic response: 95% (300 mg QW) and 96% (900 mg Q4W); ALT normalization: 60% and 44% respectively
- · HDV RNA LLOQ (<10 IU/mL) at Week 24: 31% (300 mg QW) and 22% (900 mg Q4W); TND: 14% and 11%
- · AZURE-1 Phase 3 Week 48 combined endpoint: 56% (300 mg) and 45% (900 mg); virologic response 86%/85%
- · Brelovitug was well tolerated with no new safety signals; most common adverse event was flu-like illness (17.2% and 18.5%), mostly after first dose
- · Company plans BLA submission to FDA in H1 2027, with potential U.S. commercial launch in Q4 2027 if approved
- · AZURE-4 is the second of two Phase 3 studies forming the basis of the U.S. registration package for brelovitug
10-11-2026
Bank Hapoalim BM filed its Q3 2026 13F-HR disclosing 121 holdings valued at approximately $918.8M as of September 30, 2026. The portfolio is heavily concentrated in mega-cap technology and broad-market ETFs, with Tesla ($141.7M), Vanguard S&P 500 ETF ($81.5M sole + $5.5M discretionary), Apple ($77.8M), iShares iBoxx Investment Grade Corporate Bond ETF ($67.7M sole + $5.3M discretionary), SPDR S&P 500 ETF ($69.4M sole + $39.1M discretionary), and Invesco QQQ ($42.7M) among the largest positions. However, the book is highly concentrated — the top holdings dominate while many positions are small, and several speculative/small-cap names (GoPro $56K, Innoviz $6K, Quantum X Labs $202K) reflect a long tail of minor stakes.
- · Filing signed by Adi Dauber, Head of Financial Markets Division, dated October 30, 2026, for period ended September 30, 2026
- · Portfolio includes a co-filer/related entity Peilim Portfolio Management Ltd (SEC file 028-16116)
- · Largest single equity position is Tesla at $141.7M (395,000 shares, sole voting authority)
- · Bond/ETF fixed income exposure is substantial: iShares iBoxx IG Corporate Bond ($67.7M sole + $5.3M discretionary), Vanguard Intermediate Term Bond ($27.9M), SPDR Intermediate Bond ($27.9M)
- · Several positions held with sole voting authority (e.g., Tesla, Vanguard S&P 500, SPDR S&P 500, iShares MSCI ACWI, iShares MSCI UK) versus discretionary (DFND) authority for most others
- · Long tail of very small positions including GoPro ($56K), Innoviz ($6K), Rivian convertible note ($152K), and Quantum X Labs ($202K)
- · Sector ETF allocations span Financials ($18.9M), Technology ($18.4M), Health Care ($8.8M), Industrials ($7.7M), Services ($7.6M), Consumer Discretionary ($3.7M), Energy ($268K)
- · No period-over-period comparison data is disclosed in this 13F-HR filing (holdings snapshot only)
10-11-2026
Turkcell reported 9M 2026 total revenue of TL 235,065,367 thousand, up 5.8% YoY from TL 222,094,491 thousand, while Q3 revenue rose 6.2% to TL 82,044,233 thousand. However, total gross profit slipped 1.3% to TL 62,061,678 thousand and operating profit fell 9.3% to TL 32,854,175 thousand as cost of revenue grew faster (+8.7%) than revenue, with selling/marketing (+7.9%) and other expenses (+49.8%) also rising. Net profit was essentially flat at TL 17,499,506 thousand (+0.5% YoY) and EPS edged up to TL 8.04 from TL 7.99, helped by a swing to a TL 15,049,203 thousand monetary gain versus TL 2,108,858 thousand, while finance costs jumped 59.8% to TL 34,025,285 thousand.
- · Total cost of revenue rose 8.7% to TL 173,003,689 thousand, outpacing 5.8% revenue growth and compressing gross margin.
- · Q3 2026 operating profit declined 4.7% YoY to TL 12,139,721 thousand and Q3 net profit fell 3.8% to TL 6,737,029 thousand.
- · Net finance costs narrowed to TL 2,822,230 thousand from TL 4,131,469 thousand, driven by a TL 15,049,203 thousand monetary gain versus TL 2,108,858 thousand a year earlier.
- · Income tax expense rose 12.1% to TL 12,283,535 thousand, lifting the effective tax rate to ~41.2% of pre-tax profit from ~38.3%.
- · Net cash from operating activities fell 6.0% to TL 74,383,050 thousand; cash generated from operations dropped to TL 94,767,076 thousand from TL 103,783,369 thousand.
- · Capital expenditure intensified: PP&E purchases TL 41,930,324 thousand (vs TL 33,994,295 thousand) and intangible asset purchases TL 46,825,144 thousand (vs TL 22,431,580 thousand).
- · Total borrowings climbed to TL 226,239,140 thousand at 30 September 2026 from TL 197,228,178 thousand at 31 December 2025.
- · Due to related parties jumped to TL 41,498,218 thousand (non-current TL 19,100,965 thousand + current TL 22,397,253 thousand) from TL 1,890,263 thousand at year-end 2025.
- · Cash and cash equivalents declined to TL 98,951,867 thousand from TL 114,158,364 thousand at 31 December 2025.
- · Intangible assets increased to TL 185,013,433 thousand from TL 130,508,097 thousand, and total assets grew 14.9% to TL 715,138,906 thousand.
- · Share of loss of equity accounted investees narrowed sharply to TL 248,904 thousand from TL 3,486,684 thousand.
- · Dividend paid in 9M 2026 was TL 9,281,264 thousand versus TL 11,180,163 thousand in 9M 2025.
- · Cumulative inflation applied was 158% at 30 September 2026 versus 222% at 30 September 2025, reflecting Turkish inflation accounting (TAS 29).
Get daily alerts with 10 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 50 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Filings Daily Market Digest
🇺🇸 More from United States
View all →November 11, 2026
US Pre-Market SEC Filings Roundup — November 11, 2026
US Pre-Market SEC Filings Roundup
November 10, 2026
US Pre-Market SEC Filings Roundup — November 10, 2026
US Pre-Market SEC Filings Roundup
November 10, 2026
Contract Deobligations Alert — November 10, 2026
Contract Deobligations Alert
November 10, 2026
DHS Homeland Security Contracts — November 10, 2026
DHS Homeland Security Contracts